Reversal of viral-induced systemic shock and respiratory...

Details Reversal of viral-induced systemic shock and respiratory... Reversal of viral-induced systemic shock and respiratory...

2004-04-21

2008-11-18

Campell, Bruce (Department: 1648)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

C424S085100, C424S093210, C424S078310

Reexamination Certificate

active

07452530

ABSTRACT:
This invention provides methods of inducing an antiviral response in an individual comprising administering to the individual an effective amount of a LT-B blocking agent and a pharmaceutically acceptable carrier. In particular this invention provides methods for treating viral-induced systemic shock and respiratory distress.

REFERENCES:
patent: 3773919 (1973-11-01), Boswell et al.
patent: 4485045 (1984-11-01), Regen
patent: 4544545 (1985-10-01), Ryan et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5225538 (1993-07-01), Capon et al.
patent: 5661004 (1997-08-01), Browning et al.
patent: 5670149 (1997-09-01), Browning et al.
patent: 5795964 (1998-08-01), Browning et al.
patent: 5925351 (1999-07-01), Browning et al.
patent: 6312691 (2001-11-01), Browning et al.
patent: 6403087 (2002-06-01), Browning et al.
patent: 6669941 (2003-12-01), Browning et al.
patent: 7001598 (2006-02-01), Browning et al.
patent: 7030080 (2006-04-01), Browning et al.
patent: 7060667 (2006-06-01), Browning et al.
patent: 7255854 (2007-08-01), Browning et al.
patent: 7309492 (2007-12-01), Browning et al.
patent: 2002/0039580 (2002-04-01), Browning et al.
patent: 2005/0037003 (2005-02-01), Browning et al.
patent: 2005/0281811 (2005-12-01), Browning et al.
patent: 2006/0280722 (2006-10-01), Browning et al.
patent: 2007/0116668 (2007-05-01), Browning et al.
patent: 3218121 (1983-11-01), None
patent: 0058481 (1982-08-01), None
patent: WO-92/00329 (1992-01-01), None
patent: WO-94/04679 (1994-03-01), None
patent: WO-97/04658 (1994-03-01), None
patent: WO-94/13808 (1994-06-01), None
patent: WO-96/22788 (1996-08-01), None
patent: WO-97/003687 (1997-02-01), None
patent: WO 98/17313 (1998-04-01), None
patent: WO-98/18928 (1998-05-01), None
Fields et al. Virology 3rd edition, p. 1018 & p. 1169.
Sanchez et al. J. Virol. 2004, vol. 78, No. 9, pp. 10370-10377.
Gupta et al. J. immunol. 2005, vol. 174, pp. 4198-4202.
(Warfield et al. J. Immunol. 2005, vol. 175, pp. 1184-1191.
Abe, Yashuhito et al, “Studies of Membrane-Associated and Soluble (Secreted) Lymphotoxin in Human Lymphokine-Activated T-Killer Cells in Vitro,”Lymphokine and Cytokine Research, vol. 11(2):115-121 (1992).
Arulanadam, Antonio et al, “A Soluble Multimeric Recombinant CD2 Protein Identifies CD48 as a Low Affinity Ligand for Human CD2: Divergence of CD2 Ligands during the Evolution of Humans and Mice,”J. Exp. Med., vol. 177:1439-1450 (1993).
Bethell, Delia et al, “ Pathophysiologic and Prognostic Role of Cytokines in Dengue Hemorrhagic Fever,”Journal of Infectious Diseases, vol. 177:778-782 (1998).
Beutler, B. et al, “Passive Immunization Against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin,”Science, vol. 229:869-871 (1985).
Browning, Jeffrey et al, “Characterization of Surface Lymphotoxin Forms Use of Specific Monoclonal Antibodies and Soluble Recepetors,”Jour. of Immunology, vol. 154:33-46 (1995).
Browning, Jeffrey et al, “Lymphotoxin Beta, a Novel Member of the TNF Family that Forms a Hetermeric Complex with Lymphotoxin on the Cell Surface,”Cell, vol. 72:847-856 (1993).
Chaplin, D. et al, “Cytokine regulation of secondary lymphoid organ development,”Curr. Opin. in Immunology, vol. 10:289-297 (1998).
Crowe, Paul et al, “Production of lymphotoxin (LT-Alpha) and a soluble dimeric form of its receptor using the baculovirus expression system,”Jour. of Immunological Methods, vol. 168:79-89 (1994).
Crowe, Paul et al, “ A Lymphotoxin-beta-Specific Receptor,”Science, vol. 264:707-710 (1994).
Duzgunes et al, “Liposome Targeting to HIV-Infected Cells via Recombinant Soluble CD4 and CD4-IgG Immunoadhesin,”Journal of Cell. Biochem., Suppl. 16E:77 (1992).
Eppstein, Deborah et al, “Biological activity of a liposome-encapsulated murine interferon gamma is mediated by a cell membrane receptor,”Proc. Nat'l. Acad. Sci. USA, vol. 82:3688-3692 (1995).
Fagerstam, Lars et al, “Surface Plasmon Resonance Detection in Affinity Technologies,”Handbook of Affinity Chromatography, Marcel Dekker, Inc., N.Y., pp. 229-252 (1993).
Force, Walker et al, “Mouse Lymphotoxin-beta Receptor Molecular Genetics, Ligand Binding, and Expression,”Journal of Immunology, vol. 155:5280-5288 (1995).
Hober, Didier et al, “Serum Levels of Tumor Necrosis Factor-alpha (TNF-alpha), INterleukin-6 (IL-6), and interleukin-1 beta (IL-1 beta) in Dengue-Infected Patients,”Am. Jour. Trop. Med. Hyg., vol. 48(3):324-331 (1993).
Hwang, Karl et al, “Hepatic uptake and degradation if unilamellar sphingomyelin/cholesterol liposomes: a kinetic study,”Proc. Nat'l. Acad. Sci. USA, vol. 77(7):4030-0434 (1980).
Lacy, Mark et al, “Viral Hemorrhagic Fevers,”Adv. in Pediatric Infectious Diseases, vol. 12:21-53 (1997).
Lane, Peter et al, “Activated human T cells express a ligand for the human B cell-associated antigen CD40 which participates in T cell-dependent activation of B lymphocytes,”Eur. Journal of Immunology, vol. 22:2573-2578 (1992).
Langer, Robert, “Controlled release of macromolecules,”Chemtech, vol. 12:98-105 (1982).
Langer, Robert et al, “Biocompatibility of polymeric delivery systems for macromolecules,”Jour of Biomedical Materials Research, vol. 15:267-277 (1981).
Mackay, Fabienne et al, “Cytotoxic Activities of Recombinant Soluble Murine Lymphotoxin-alpha and Lymphotoxin-alpha/beta Complexes,”Jour. of Immunology, vol. 159:3299-3310 (1997).
Mauri, Davide et al, “Light, a New Member of the TNF Superfamily, and Lymphotoxin alpha are Ligands for Herpesvirus Entry Mediator,”Immunity, vol. 8:21-30 (1998).
Miller, Glenn et al, “Specific Interaction of lymphocyte Function-associated Antigen 3 with CD2 can Inhibit T Cell Responses,”Jour. Experimental Medicine, vol. 178:211-222 (1993).
Montgomery, Rebecca et al, “Herpes Simplex Virus-1 Entry into Cells Mediated by a Novel Member of the TNF/NGF Recpetor Family,”Cell, vol. 87:427-436 (1996).
Morrison, Sherie, “In Vitro Antibodies: Strategies for Production and Application,”Annal Review of Immunology, vol. 10:239-265 (1992).
Morrison, Sherie et al, “Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains,”Proc. Nat'l Academy of Sciences USA, vol. 81:6851-6855 (1984).
Pass, Harvey et al, “The Macrophage, TNF, and other Cytokines,”Chest Surgery Clinics of North America, vol. 5(1):73-90 (1995).
Queen, Cary et al, “A humanized antibody that binds to the interleukin 2 recpetor,”Proc. Natl'l. Acad. Sci. USA, vol. 86:10029-10033 (1989).
Roitt et al, Immunology, 3rd ed., pp. 4.8 (1993).
Sheehan, Kathleen et al, “Generation and Characterization of Hamster Monoclonal Antibodies that Neutralize Murine Tumor Necrosis Factors,”Jour. of Immunology, vol. 142(11):3884-3894 (1989).
Sidman, Kenneth et al, “Controlled Release of Macromolecules and Pharmaceuticals from Synthetic Polypeptides Based on Glutamic Acid,”Biopolymers, vol. 22:547-556 (1983).
Smith, Craig et al, “The TNF Receptor Superfamily of Cellular and Viral Proteins: Activation, Costimulation, and Death,”Cell, vol. 76:959-962 (1994).
Traunecker, Andre et al, “Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules,”Nature, vol. 339:68-70 (1989).
Winter, Greg et al, “Man-made antibodies,”Nature, vol. 349:293-299 (1991).
Wong, Grace et al, “Tumour necrosis factors alpha and beta inhibit virus replication and synergize with interferons,”Nature, vol. 323:819-822 (1986).
Zhou, M. et al, “Real-Time Measurements of Kinetics of EGF Binding to Soluble EGF Receptor Monomers and Dimers Support the Dimerization Model for Receptor Activation,”Biochemistry, vol. 32:8193-8198 (1993).
Nicola, Anthony V. et al., “Monoclonal Antibodies to Distinct Site

Affiliated with

Also associated with

Rating

Reversal of viral-induced systemic shock and respiratory... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Reversal of viral-induced systemic shock and respiratory..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reversal of viral-induced systemic shock and respiratory... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4029649